JR10 E-cigarette | Lighting Up the Future of Smoking Alternatives

Jan.14.2025
 JR10 E-cigarette | Lighting Up the Future of Smoking Alternatives

Making smoking healthier and more personalized, the JR10 e-cigarette is specially designed for the UK market and future European markets. With its excellent design and attractive appearance, it stands out as a leader among smoking alternatives.

 

 JR10 E-cigarette | Lighting Up the Future of Smoking Alternatives
The stylish and simple JR10 e-cigarette features a semi-transparent cartridge design and colorful lights that instantly catch the eye.

 

 

Core Highlights: Long-lasting Battery Life and Powerful Performance

 

 

The JR10 is equipped with a 650mAh rechargeable battery, supporting USB-C fast charging. It can be fully charged in less than an hour, allowing you to maintain smooth use whether at home, in the office, or on the go. Coupled with a large 2+10ML semi-transparent cartridge, it supports approximately 10,000 draws, truly achieving a perfect balance of efficiency and long-lasting battery life.

 

Imagine: No need for frequent charging and oil refills, easily meeting the needs of the whole day, making your life more convenient and efficient.

 

 JR10 E-cigarette | Lighting Up the Future of Smoking Alternatives
The semi-transparent cartridge design, makes the oil level clear at a glance, saying goodbye to dry burns and worries; the screen displays the battery level in real-time, making use smarter.

 

 

Colorful Lights Add Fun to the Experience

 

 

Every draw lights up the semi-transparent cartridge with a rainbow of colors, providing a cool visual experience. This is not just a function but also a fashion statement, suitable for modern users who pursue personalization.

 

 

Automatic Airflow Activation Mechanism, Mouth-to-Lung (MTL) Style for a More Natural Fit

 

 

The JR10 adopts an automatic airflow activation mechanism, no button operation is needed, just pick up and use, especially suitable for users who prefer the MTL (mouth-to-lung) drawing style, with a smooth and natural draw.

 

 JR10 E-cigarette | Lighting Up the Future of Smoking Alternatives
Users enjoy the JR10 effortlessly, with the MTL design closer to the traditional smoking sensation, satisfying the need for a real smoking experience.

 

 

Details are King: Thoughtful Design for Every Moment

 

  • Battery Level Screen Display: Always in control of the device status, no need to worry about the battery running out suddenly.
  • 20mg Nicotine Concentration: Precise control of nicotine cravings, meeting needs while complying with the strict regulations of the European market.
  • Semi-transparent cartridge Design: Clear oil level visibility, more worry-free use.

 

 

Born for the Future: A Dual Commitment to Safety and Environmental Sustainability

 

 

As an innovative product focused on the UK and European markets, the JR10 not only complies with local laws and health standards but also offers sustainable choices through more environmentally friendly designs.

 

The above 2+10 product is developed by Lanavape, which has not yet been officially launched on the website.

 

LANAVAPE is a well-known e-cigarette brand factory headquartered in Shenzhen, China, ranking in the top five in the Southeast Asian market and trusted by consumers. The company focuses on the research and production of disposable, Replaceable pod, and open pod-style e-cigarettes. Now, LANAVAPE is actively expanding into the European market, offering healthier and more efficient smoking alternatives to users worldwide.

Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Smoore’s first-half 2026 revenue rose 19.9%, but the results revealed growing structural risks beneath the headline growth. Heat-not-burn contributed about 61% of incremental revenue and remains driven largely by one core customer, while traditional vaping markets diverged, own-brand growth slowed and China enterprise revenue declined further. Gross profit and adjusted profit lagged revenue growth, while second-quarter revenue growth slowed to about 1.9%, putting greater focus on the quality, concentration and sustainability of Smoore’s expansion.
Capital Markets
Aug.20
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
AIR’s first half-year results as a listed company offer a new test of how far a traditional hookah business can transform. H1 2026 revenue rose 3.7%, even as Flavored Shisha Molasses shipments fell 9%, with pricing and mix supporting growth. Traditional shisha still generates almost all revenue, while OOKA, Crown Switch, Greentank and U.S. regulatory spending point to accelerating diversification. The next test is whether those investments can become a second business of meaningful scale and profitability.
Capital Markets
Aug.21
Philip Morris Romania Executive on Smoke-Free Strategy: How IQOS Spaces Are Moving Beyond Retail to Consumer Connection
Philip Morris Romania Executive on Smoke-Free Strategy: How IQOS Spaces Are Moving Beyond Retail to Consumer Connection
In an interview with Romanian marketing publication IQads, Marek Gębski, Director of Smoke-Free Products at Philip Morris Romania, said IQOS experience spaces are evolving from traditional retail locations into platforms for consumer engagement and brand connection. Through locations such as IQOS Boutique Victoriei, PMI aims to use design, culture and consumer experiences to strengthen communication with adult consumers about smoke-free products. The interview highlights how tobacco companies are expanding smoke-free strategies beyond products toward experiential marketing and consumer relationships.
Aug.11
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11